Annovis Bio Competitors

Annovis Bio (NYSE:ANVS) and Gemini Therapeutics (NASDAQ:GMTX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, valuation and institutional ownership.

Profitability

This table compares Annovis Bio and Gemini Therapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Annovis Bio and Gemini Therapeutics, as reported by MarketBeat.com.

Gemini Therapeutics has a consensus target price of $22.00, suggesting a potential upside of 66.41%. Given Gemini Therapeutics' higher probable upside, analysts plainly believe Gemini Therapeutics is more favorable than Annovis Bio.

Earnings & Valuation

This table compares Annovis Bio and Gemini Therapeutics' top-line revenue, earnings per share and valuation.

Summary

Gemini Therapeutics beats Annovis Bio on 2 of the 2 factors compared between the two stocks.

Annovis Bio (NYSE:ANVS) and Sigilon Therapeutics (NASDAQ:SGTX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, valuation and institutional ownership.

Profitability

This table compares Annovis Bio and Sigilon Therapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Annovis Bio and Sigilon Therapeutics, as reported by MarketBeat.com.

Sigilon Therapeutics has a consensus target price of $53.75, suggesting a potential upside of 202.65%. Given Sigilon Therapeutics' higher probable upside, analysts plainly believe Sigilon Therapeutics is more favorable than Annovis Bio.

Earnings & Valuation

This table compares Annovis Bio and Sigilon Therapeutics' top-line revenue, earnings per share and valuation.

Summary

Sigilon Therapeutics beats Annovis Bio on 2 of the 2 factors compared between the two stocks.

Annovis Bio (NYSE:ANVS) and Inventiva (NYSE:IVA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, valuation and institutional ownership.

Profitability

This table compares Annovis Bio and Inventiva's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Annovis Bio and Inventiva, as reported by MarketBeat.com.

Inventiva has a consensus target price of $27.3333, suggesting a potential upside of 89.31%. Given Inventiva's higher probable upside, analysts plainly believe Inventiva is more favorable than Annovis Bio.

Earnings & Valuation

This table compares Annovis Bio and Inventiva's top-line revenue, earnings per share and valuation.

Summary

Inventiva beats Annovis Bio on 2 of the 2 factors compared between the two stocks.

Annovis Bio (NYSE:ANVS) and Terns Pharmaceuticals (NASDAQ:TERN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, valuation and institutional ownership.

Profitability

This table compares Annovis Bio and Terns Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Annovis Bio and Terns Pharmaceuticals, as reported by MarketBeat.com.

Terns Pharmaceuticals has a consensus target price of $30.50, suggesting a potential upside of 61.12%. Given Terns Pharmaceuticals' higher probable upside, analysts plainly believe Terns Pharmaceuticals is more favorable than Annovis Bio.

Earnings & Valuation

This table compares Annovis Bio and Terns Pharmaceuticals' top-line revenue, earnings per share and valuation.

Summary

Terns Pharmaceuticals beats Annovis Bio on 2 of the 2 factors compared between the two stocks.

Annovis Bio (NYSE:ANVS) and Angion Biomedica (NASDAQ:ANGN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, valuation and institutional ownership.

Profitability

This table compares Annovis Bio and Angion Biomedica's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Annovis Bio and Angion Biomedica, as reported by MarketBeat.com.

Angion Biomedica has a consensus target price of $59.3333, suggesting a potential upside of 283.29%. Given Angion Biomedica's higher probable upside, analysts plainly believe Angion Biomedica is more favorable than Annovis Bio.

Earnings & Valuation

This table compares Annovis Bio and Angion Biomedica's top-line revenue, earnings per share and valuation.

Summary

Angion Biomedica beats Annovis Bio on 2 of the 2 factors compared between the two stocks.

Annovis Bio (NYSE:ANVS) and Sensei Biotherapeutics (NASDAQ:SNSE) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, valuation and institutional ownership.

Profitability

This table compares Annovis Bio and Sensei Biotherapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Annovis Bio and Sensei Biotherapeutics, as reported by MarketBeat.com.

Sensei Biotherapeutics has a consensus target price of $29.50, suggesting a potential upside of 108.78%. Given Sensei Biotherapeutics' higher probable upside, analysts plainly believe Sensei Biotherapeutics is more favorable than Annovis Bio.

Earnings & Valuation

This table compares Annovis Bio and Sensei Biotherapeutics' top-line revenue, earnings per share and valuation.

Summary

Sensei Biotherapeutics beats Annovis Bio on 2 of the 2 factors compared between the two stocks.